Background-Vitamin D, in addition to its established role in bone metabolism, may regulate the immune system and impact the outcome of allografts.
Conclusions-Vitamin D deficiency is an independent risk factor for development of ACR

INTRODUCTION
In addition to its role in calcium-phosphorous-bone metabolism, Vitamin D is considered to participate in a wide range of biologic processes, and vitamin D deficiency/insufficiency has been associated with all-cause mortality in humans (Reviewed in (1)). A role for vitamin D and its metabolites in regulating both innate immunity and adaptive immunity has also been reported. Administration of Vitamin D has been shown to be beneficial in experimental models of transplantation. 1,25-dihydroxyvitamin D3 (1,25(OH) 2 D3) administration prevented acute rejection and prolonged survival in the ACI to Lewis rat renal transplant model (2) , and also prevented chronic allograft nephropathy in the Fisher 344 to Lewis rat renal transplantation model (3) . An allograft protective effect of 1,25(OH) 2 D3 has also been reported in orthotopic rat liver transplantation models (4, 5) .
Mechanistic studies of vitamin D have elucidated pathways by which vitamin D may regulate immunity. Calcitriol inhibits both PHA-induced proliferation of human peripheral blood mononuclear cells (PBMC) and PHA-induced production of interleukin-2 by PBMC (6). Reichel and colleagues reported that vitamin D inhibits interferon-gamma production by human PBMC and enriched T cells at the pre-translational level (7) . Oral calcitriol treatment of stable kidney graft recipients has been associated with a decreased display of HLA-DR and the co-stimulatory molecules CD28, CD40, and CD86 on the surface of peripheral blood leukocytes (8) . In a randomized controlled trial of 19 recipients of living donor kidney grafts, calcitriol treatment of kidney donors and recipients was associated with an increased percentage of CD3+CD4+CD25+ cells in peripheral blood compared to the untreated group (9) . Application of 1,25(OH) 2 D3 to the skin of mice is associated with alterations in the phenotype of CD11c+ dendritic cells and enhanced regulatory activity of CD4+CD25+ cells in draining lymph nodes (10) .
Although previous studies have suggested that vitamin D deficiency has an adverse effect on allograft outcomes, there has been heterogeneity in the thresholds used to classify patients as vitamin D deficient or sufficient. Kim and colleagues defined vitamin D deficiency as circulating levels less than 10 ng/mL of 25(OH)D and reported lower eGFR in vitamin D deficient kidney graft recipients (11) . Bienaimé et al. used a level of 15 ng/mL and reported that vitamin D is an independent risk factor for lower measured GFR and interstitial fibrosis and tubular atrophy (12) .
The lack of uniformity in cutoff points for Vitamin D deficiency has been recently addressed by the 2011 guidelines developed by the Task Force of the Endocrine Society, which recommends measuring circulating levels of 25(OH)D rather than levels of 1,25-dihydroxyvitamin D [1,25(OH) 2 D] for assessing vitamin D status and defines vitamin D deficiency as circulating levels less than 20 ng/mL (13) . Herein, we adapted the Endocrine Society's diagnostic guideline and investigated the association between post-transplant vitamin D status and the incidence of acute cellular rejection, CMV disease, and BK virus nephropathy during the first year of transplantation and kidney allograft function at 1 year in our single center study of 351 kidney graft recipients.
RESULTS
One thousand two hundred and eleven patients received a kidney allograft at our center during the period January 2005 to December 2010, and the baseline characteristics are listed in Table 1A . Among the 1211 patients, 351 had circulating levels 25(OH)D measured within the first 30 days of transplantation and the remaining 860 did not have levels measured during the same period. Variables such as age of the recipients, gender, type of donor graft (living donor vs. deceased donor), prior history of transplantation, or induction therapy with anti-thymocyte globulin were not different between the two groups. African American race (P<0.01) and diabetes mellitus (P=0.06) were, however, over represented in the group without measured levels of vitamin D. The incidence of biopsy confirmed acute cellular rejection (ACR) was higher in the 25(OH)D measured cohort compared to the 25(OH)D unmeasured cohort (7.7% vs. 4.3%, P=0.02, Fisher's Exact Test) and the incidence of CMV disease and that of BKV nephropathy were not different between the two groups.
Circulating Levels of 25-hydroxyvitamin D in the 351 Kidney Allograft Recipients with Levels Measured within 30 Days of Transplantation
The mean (±SD) 25(OH)D level in the our study cohort of 351 kidney graft recipients was 20.2±11.1 ng/mL. Figure 1 illustrates the distribution of 25(OH)D levels among all 351 patients. Using the Endocrine Society Consensus guidelines (13) classification for vitamin D deficiency (circulating levels of 25(OH) D less than or equal to 20 ng/mL) or sufficiency (circulating levels of 25(OH)D greater than 20 ng/mL), 216 (61.5%) of the 351 patients were classified as vitamin D deficient and the remaining 135 patients (38.5%) were classified as vitamin D sufficient.
Pre-transplant characteristics of the kidney graft recipients, stratified by 25(OH)D levels, are summarized in Table 1B . The vitamin D deficient group was more likely to be female (43% vs. 28%, P=0.007, Fisher's Exact test), African American (29% vs. 11%, P<0.001), and have diabetes (31% vs. 22%, P=0.07) than the vitamin D sufficient group. The vitamin D sufficient group was more likely to have a preemptive kidney transplantation (31% vs. 17%, P=0.002).
Serum PTH levels were significantly higher in the vitamin D deficient group compared to the sufficient group (321±368 vs. 238±272 pg/mL, P<0.001, Wilcoxon-Rank Sum test), The vitamin D sufficient group had a marginally higher serum calcium (9.2±0.9 vs. 9.0±1.0, P=0.06) than the deficient group.
Age at the time of transplantation, organ donor type (deceased donor vs. living donor), history of prior kidney transplantation, timing of 25(OH)D measurement (winter vs. summer), serum phosphorus, and serum alkaline phosphatase were not associated with vitamin D status (Table 1B) .
Among the 351 kidney graft recipients, 303 received anti-thymocyte induction therapy while the remaining 47 patients receiving anti-CD25 monoclonal antibody therapy (1 patient received alefacept induction); 73 patients received maintenance corticosteroids while 271 did not receive maintenance corticosteroids (corticosteroids stopped on day 4 posttransplantation). The vitamin D deficient patients were not significantly different from the vitamin D sufficient patients in terms of anti-thymocyte induction therapy or corticosteroid maintenance therapy (Table 1B) .
Vitamin D Status and Biopsy Confirmed Acute Cellular Rejection
Biopsy confirmed acute cellular rejection (ACR) within the first year of kidney transplantation occurred in 27 (7.7%) of the 351 kidney graft recipients evaluated for vitamin D status. ACR was significantly more frequent in the vitamin D deficient group (N=22, 10.2%) than in the sufficient group (N=5, 3.7%) (P=0.04, Fisher's Exact Test). The number of patients with ACR by circulating levels of 25(OH)D intervals is shown in Figure  2A . Kaplan-Meier analysis of time to development of ACR demonstrated that patients with vitamin D deficiency were at greater risk of developing ACR within the first year of transplantation compared to those without the deficiency ( Figure 2B ; log rank test: P=0.03).
Independent variables that were associated with development of ACR using univariate Cox Regression analysis (P<0.10) included vitamin D deficiency, antithymocyte globulin induction therapy, deceased donor kidney transplantation, and female gender. On the other hand, African American race, preemptive transplantation, prior transplantation, corticosteroid maintenance, and PTH levels were not associated with ACR in the first year after transplantation (Table 2A) . After adjustment for variables with a P<0.10, the multivariable analysis confirmed that vitamin D deficiency was an independent risk factor for ACR (HR: 3.3, 95% confidence intervals (CI): 1.2-8.7, P=0.02). The use of antithymocyte globulin induction therapy was associated with a reduced risk of ACR and deceased donor transplantation with an increased risk, as aniticipated (Table 2A) . Among the 78 patients who received 1,25(OH) 2 D3, the incidence of ACR during the first year of transplantation was 5.1% compared with 14.5% in the 55 patients who received 25(OH)D only and 12.0% in the 83 patients who received neither 1,25(OH) 2 D3 nor 25(OH)D. Thus, in the 25(OH)D deficient group, exposure to 1,25(OH) 2 D3 was associated with a lower rate of ACR compared to those not treated with 1,25(OH) 2 D3 (5.1% vs. 13.0%, P=0.099). In the 78 patients who received 1,25(OH) 2 D3, all 4 patients who developed ACR did receive 1,25(OH) 2 D3 prior to the ACR event. Table 2B shows the impact of supplementation with 1,25(OH) 2 D3 on the risk of ACR. In complete agreement with the notion that vitamin D deficiency is a risk factor for ACR, the hazard ratio for ACR increased from 3. 
Vitamin D Status and Post-Transplant Viral Infections
The incidence of CMV disease and BK virus associated nephropathy during the first year of transplantation was similar in the vitamin D deficient group and the sufficient group. CMV disease occurred in 13 patients (6.0%) in the deficient group compared to 8 patients (5.9%) in the sufficient group during the first year of transplantation (P=0.99). When stratified by CMV donor/recipient antibody status, there was no significant difference in CMV incidence between the vitamin D deficient group and the vitamin D sufficient group (Supplemental Digital Content [SDC] Table S1 ).
Our center utilizes a CMV prophylaxis strategy rather than a CMV screening strategy and 345 of the 351 transplant recipients received valgancyclovir prophylaxis during the first 6 months of transplantation and only 6 transplant recipients received acyclovir. The almost universal use of CMV prophylaxis precluded meaningful analysis of the association between prophylaxis and ACR.
BK virus associated nephropathy occurred in 3 (1.4%) in the deficient group compared to 2 (1.5%) in the sufficient group during the first year of transplantation (P=0.99). Two hundred and forty-six of 351 transplant recipients had a BK virus level measured during the first year of transplantation. BK viremia based on a definition of >1000 copies/mL was not significantly different between those that were 25(OH)D sufficient and those that were 25(OH)D deficient (18.6% vs. 13.1%, P=0.23).
Vitamin D Status and Allograft Function
Box and whisker plots of the eGFR measured at the time of measurement of 25(OH)D levels in the vitamin D sufficient or deficient group are shown in Figure 3A ; the mean (±SD) eGFR was 39.8±17.8 mL/min/1.73m 2 in the sufficient group and 39.3±21.8 mL/min/1.73m 2 in the deficient group (P=0.45, Wilcoxon-Rank Sum test). Serum creatinine levels at 1 year after transplantation were available in 321 of the 351 kidney graft recipients evaluated for vitamin D status. At 1 year post-transplantation, eGFR was 50.9±18.5 mL/min/1.73m 2 in the vitamin D sufficient group and 52.6±21.7 mL/min/1.73m 2 in the deficient group at 1 year (P=0.71, Figure 3B) . We repeated the analysis after excluding the kidney graft recipients who had an episode of ACR within 12 months of transplantation. eGFRs was again not significantly different between the vitamin D sufficient group and the deficient group (52.1±17.4 mL/min/m2 vs. 53.9±21.7 mL/min/m2, respectively, P=0.56) ( Figure 3C ).
DISCUSSION
Using the Endocrine Society Clinical Practice guidelines to characterize vitamin D deficiency, we found that a circulating level of 25(OH)D less than 20ng/mL is an independent risk factor for biopsy confirmed ACR in kidney graft recipients in the first year post transplantation even after controlling for timing of follow up and important potential confounders such as type of induction therapy, donor organ type, and gender.
Our demonstration that vitamin D deficiency is associated with ACR confirms and extends earlier reports. Ma and colleagues performed a cross sectional study of 94 kidney graft recipients and reported that patients who had a history of acute rejection had a significantly lower level of 25(OH)D than those who did not have a history of acute rejection (14) . Kim et al. examined the 25(OH)D levels prior to kidney transplantation and reported that patients with 25(OH)D deficiency, defined as less than 10 ng/mL, had a higher incidence of biopsy proven acute rejections than those with levels greater than 10ng/mL (11) . Different cutoff points for vitamin D deficiency were used in these studies, and the impact of important confounders such as therapy, donor organ type, and age were not addressed.
The association between 25(OH)D levels and ACR has been noted in recipients of organs other than kidneys. In a study of 133 liver transplant recipients, pre-transplant circulating levels less than 5 ng/mL of 25(OH)D levels were independently associated with moderateto-severe ACR episodes within 2 months post transplantation (15) . In a study of 102 lung transplant recipients, those with 25(OH) D levels less than 30ng/mL had more episodes of ACR and more aggressive ACR during the first year post transplantation than those with levels greater than 30ng/mL (16) . 1, 21) ). The impact of vitamin D deficiency on infections in organ graft recipients, however, has not been fully characterized. In the current study, we did not find a significant association between vitamin D deficiency and two common post-transplant diseases -CMV disease and BK virus nephropathy. Our analysis of the relationship between vitamin D status and CMV disease and BK virus nephropathy, however, must be interpreted with caution in view of the relatively small number of events in our study cohort.
The mechanism for the association of vitamin D status and kidney graft function is not known. A large, single center study of 634 kidney graft recipients found that circulating levels less than 15 ng/mL of 25(OH)D at 3 months post transplantation is an independent risk factor for lower measured GFR and interstitial fibrosis and tubular atrophy at 1 year post transplantation (12). We did not find an association between vitamin D deficiency and 1 year allograft function as some retrospective studies have found (11, 12) .
The strengths of our study design include the measurement of 25(OH)D status within the first month of transplantation, the use of a pre-specified definition of vitamin D deficiency (circulating levels of 25(OH)D less than 20 ng/mL) as defined by the Endocrine Society, and the availability of 1 year follow up data on all patients. Limitations of our study include the lack of serial 25(OH)D levels which may have fluctuated during the first year of transplantation, the potential for unmeasured confounders of the relationship between vitamin D status and renal function/allograft status, and the use of eGFR rather than iohexal or inulin to measure GFR. Because only 351 of the 1211 transplant recipients from January 2005 to December 2010 had measured 25(OH)D levels for analysis and the remaining 860 did not, a selection bias may have existed within our study. It should be noted, however, that there are no evidence-based guidelines for screening patients for vitamin D status in the post-transplantation period, and screening at the current time is primarily physician's choice. The findings from this study that vitamin D deficiency is associated with ACR, and that supplementation with active vitamin D may reduce this risk suggests that issues related to screening vitamin D levels in the post-transplantation period and treatment in those found to be vitamin D deficient require evaluation in properly designed clinical trials. Additionally, the incidence of ACR was lower in the 860 patients without vitamin D measurement in the 30 days of transplantation compared to the 351 patients with vitamin D measurement during the same time interval. The basis for the lower incidence is difficult to elucidate in part due to retrospective cohort research design. It should be noted, however, that the 7.7% incidence of ACR in the group with vitamin D measurement is not higher than the incidence reported for recipients of kidney allografts in the US (22) .
Despite these limitations, our observations, together, support the conduct of appropriately designed clinical trials to investigate the role of vitamin D supplementation in kidney graft recipients. 
METHODS
Clinical Course and Outcomes
The kidney graft recipients were managed with the use of our center protocol. The recipients received induction therapy in the form of either antithymocyte globulin or IL-2 receptor antibody therapy, and received maintenance immunosuppressive therapy comprised of tacrolimus and mycophenolate mofetil or mycophenolic acid, with or without maintenance corticosteroids. ACR was biopsy confirmed in each instance.
Estimated GFR
eGFR at the time of vitamin D measurement and at 1 year post transplantation were calculated using the 4 variable MDRD equation. The value of eGFR at 1 year was determined using the creatinine measurement closest to 365 days post transplantation. eGFRs measured more than 90 days from day 365 post transplantation were excluded from the analysis.
Infections
Transplant recipient's records were reviewed for occurrence of CMV disease and BK virus nephropathy (BKVAN) during the first year of transplantation. BKVAN diagnosis was based on kidney allograft biopsy showing SV40 positive staining. CMV disease diagnosis was based on a positive blood PCR or pp65 antigenemia and evidence of organ involvement. BK viremia was defined as greater than 1000 copies of BK virus DNA per mL of plasma.
Statistical Analysis
Categorical variables were compared using Fisher's Exact tests, and continuous variables were compared using Wilcoxon Rank-Sum tests. Kaplan-Meier curves were constructed and compared using a log-rank test. To evaluate the risk factors associated with ACR, univariate Cox regression analysis was performed. Variables with a P value of <0.1 were included in a multivariable Cox proportional hazards regression to identify independent risk factors for ACR. Statistical analyses were performed using STATA 12.0 I/C (Statacorp, College Station, TX). For all analyses, we performed 2-sided tests and confidence intervals with type I error of 5%.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Multivariable Cox regression was used to determine whether vitamin D deficiency was associated with ACR within the first year of transplantation. Characteristics associated with ACR in a univariate Cox regression analysis (P<0.10) were included in the multivariable analysis for the identification of independent risk factors associated with ACR. Hazard ratios (HR) with 95% confidence interval (CI) and P value are reported. Highlighted in bold are the variables associated with ACR with a P value of less than 0.10.
a PTH was available only in 335 transplant recipients. Univariate analysis was performed for this factor based on the 335 transplant recipients. c PTH was available only in 335 transplant recipients. Univariate analysis was performed for this factor based on the 335 transplant recipients.
